Reshma L. Mahtani DO
Chief of Breast Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FloridaBiographical Sketch:
Dr. Reshma L. Mahtani is a medical oncologist practicing in South Florida. She serves as Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida (a Memorial Sloane Kettering affiliate). She is specialized in the treatment of breast cancer.
After completing her master of science degree in neuroscience at the University of Connecticut, Dr. Mahtani went on to the University of New England College of Osteopathic Medicine, where she received her medical degree. She completed internship at Greenwich Hospital, a Yale-affiliate, in Greenwich, Connecticut, and undertook residency training at St. Vincent’s Catholic Medical Center in New York, where she also completed her fellowship.
Prior to assuming her role at the Miami Cancer Institute, Dr. Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She is an active clinical researcher and her research focuses on novel therapies for the treatment of breast cancer. She has made significant scientific and clinical practice contributions with numerous first-author publications in peer-reviewed journals.
She has served on the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee and as a member of the editorial board of The Breast Journal. She has been Program Director for several officially licensed Best of ASCO programs and is the Director of the ASCO Highlights series. She has a passion for medical education and founded a medical education initiative to ensure that physicians in South Florida know about the latest cancer treatments and can provide evidence-based care. Finally, she is involved in several initiatives that enhance patients’ access to healthcare, as well as community collaborations for education and advocacy.
Positions:
Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida
Degrees:
DO: University of New England College of Osteopathic Medicine
MS (Neuroscience): University of Connecticut
Postgraduate Training:
Fellowship: St. Vincent’s Catholic Medical Center, New York, New York
Certificate:
Harvard Global Clinical Scholars Training Program
Clinical Interests:
Breast cancer, novel therapeutics
Disclosures
Reshma L. Mahtani, DO, has served as a consultant/advisor for Agendia, Amgen, Astra Zeneca, Daiichi, Eisai, Genentech, Gilead, Hologic, Lilly, Merck, Novartis, Pfizer, Puma, Sanofi, Sermonix, Stemline, SeaGen.
Contracted research: Gilead
Recent Contributions to PracticeUpdate:
- Outcomes of Tucatinib Combination Treatment After Trastuzumab Deruxtecan Therapy in Patients With ERBB2-Positive Metastatic Breast Cancer
- Weight, Cardiometabolic, and Hormonal Outcomes of Whole-Food, Plant-Based Diet in Patients With Metastatic Breast Cancer
- ESR1 Mutation Prevalence and Genomic Landscape Alterations in CDK4/6i-Treated HR+/HER2− Breast Cancer
- Longitudinal Profiling Identifies Co-Occurring BRCA1/2 Reversions and TP53BP1, RIF1, and PAXIP1 Mutations in PARP Inhibitor–Resistant Advanced Breast Cancer
- Toripalimab + Nab-Paclitaxel for Metastatic/Recurrent TNBC
- Pertuzumab Plus High-Dose Trastuzumab for HER2-Positive Breast Cancer With Brain Metastases
- 2023 Top Story in Metastatic Breast Cancer: Kicking the Can Down the Road—Delaying the Use of Chemotherapy in Hormone Receptor–Positive Metastatic Breast Cancer With Novel Endocrine and Targeted Treatment Options
- SABCS 2023: Abstract Recommendations From Dr. Reshma Mahtani for Breast Cancer
- Overall Survival and Exploratory Biomarker Analyses in Patients With HR+/HER2+ Metastatic Breast Cancer Receiving Abemaciclib Plus Trastuzumab ± Fulvestrant vs Trastuzumab Plus Chemotherapy
- Patritumab Deruxtecan, a HER3-Directed Antibody–Drug Conjugate, for Heavily Pretreated HER3-Expressing Metastatic Breast Cancer